Dexcel Pharma Technologies Ltd. - 01 Oct 2021 Form 3 Insider Report for Roivant Sciences Ltd. (ROIV)

Reporting relationship: 10%+ Owner
Issuer ticker: ROIV
Reported as of: 01 Oct 2021
Net transaction value: $0
SEC form: 3
Accepted by SEC: 01 Oct 2021, 17:02:10 UTC
Prior SEC filing: 03 Jun 2021
Next SEC filing: 26 Apr 2022
Source filing: View source filing
Reporting owner signature: /s/ Dexcel Pharma Technologies Ltd. by Dan Oren, Executive Chairman

Key filing fact

Dexcel Pharma Technologies Ltd. filed Form 3 for Roivant Sciences Ltd. (ROIV) on 01 Oct 2021.

Key facts

This page summarizes Dexcel Pharma Technologies Ltd.'s Form 3 filing for Roivant Sciences Ltd. (ROIV).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 01 Oct 2021, 17:02.

Change

Previous filing in this sequence was filed on 03 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ROIV holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 98,809,158
Date: 01 Oct 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 643,845 common shares. Dexxon Holdings Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity.